sábado, 28 de febrero de 2026
Perspective on Using Artificial Intelligence in Alcohol Research and Treatment: Opportunities and Ethical Considerations David I.K. Moniz-Lewis,1,2 ORCID logo Megan Kirouac,2 ORCID logoMatison W. McCool,2 ORCID logoFrank J. Schwebel,2 ORCID logoand Katie Witkiewitz1,2
https://arcr.niaaa.nih.gov/volume/45/1/perspective-using-artificial-intelligence-alcohol-research-and-treatment-opportunities?utm_source=arcr-email&utm_medium=email&utm_campaign=witkiewitz-2025-12&utm_content=arcr-listserv
Many people who might benefit from treatment for alcohol use disorder never receive care, and better identification and treatment access for these individuals is urgently needed. A new Alcohol Research: Current Reviews Perspective article explores how artificial intelligence (AI)-based approaches such as machine learning, large language models (e.g., “chatbots”), and data analysis tools may be utilized to advance alcohol research, screening, and treatment. Research has found that such approaches show promise for screening and providing evidence-based psychotherapy to more individuals; however, they must be implemented in an ethical and bias-free manner to realize their full potential.
Study measuring changes in protein structure establishes new class of Alzheimer’s biomarkers
Study measuring changes in protein structure establishes new class of Alzheimer’s biomarkers
NIH-funded insights into Alzheimer’s biology could help with early diagnosis, future clinical trials
https://www.nih.gov/news-events/news-releases/study-measuring-changes-protein-structure-establishes-new-class-alzheimers-biomarkers
In a study supported by the National Institutes of Health (NIH), researchers have identified a new type of blood-based biomarker test for Alzheimer’s disease that measures structural changes in proteins, providing more information on the underlying biology of the disease than standard blood tests. The findings, published in Nature Aging, also provide new insights into how Alzheimer’s disease biology may differ between males and females.
TURNING THE TIDE FOR RARE DISEASE
https://rarerevolutionmagazine.com/category/rare-insights/turning-the-tide-for-rare-disease/
Michèle Melhem, head of rare disease, International Center of Excellence at Biogen discusses the need for urgent and authentic multi-stakeholder collaboration to co-create solutions that could accelerate rare disease innovation, underscoring Biogen’s commitment to true patient-centricity
Every day, families living with rare diseases face a reality few can imagine; years of uncertainty, unanswered questions and decisions made without clear guidance. For many, the journey begins with a long wait, with research showing that an accurate diagnosis takes an average of 4-8 years.1 Parents watch key childhood milestones slip by while searching for answers that feel just out of reach. Even when a diagnosis comes, hope is often tempered by the fact that most rare conditions still have no approved treatment.
Rare Disease Day 2026 is here and so is our latest spotlight edition!
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=b226070d-f1dd-4177-bfbc-65a7f9ba2588
Our flagship Rare Disease Day 2026 spotlight edition is here—bringing you a deep dive into the global movement transforming care, research and advocacy for Rett syndrome
We are proud to share the voices of leading experts, clinicians and advocates who are moving beyond the status quo:
Global progress: Insights into the first international guidelines for communication in Rett syndrome (Dr. Gillian Townend) and the pivotal meeting that brought Rett to the heart of the European Parliament (Dr. Nadia Bahi-Buisson).
The future of data: Introducing Rett X, the new European patient registry uniting families, clinicians and researchers for faster, more ethical clinical trials (Pedro Rocha).
Care beyond medicine: Examining the full 'Burden of Illness'—including the emotional and financial strain on families—and the call for policy reform (Dr. Mariëlle van den Berg).
Innovation in assessment: How systematic home video capture is revolutionising clinical assessment, outcome measures and future decentralised trials (Professor Jenny Downs).
The power of early intervention: A look at the hunt for "hidden" early biomarkers (Peter Marschik) and the importance of multidisciplinary, connected care (Erin O’Connor Prange & Dr. Giulia Prato).
You can view this publication from a desktop, laptop, mobile or tablet and it is packed with interactive links so you can enjoy the best possible experience when engaging with the content. And don't forget you can also view from our website at any time along with lots of other great digital content.
NEDAW 2026 Toolkit
https://womenshealth.gov/nedaw/resources?utm_medium=email&utm_source=govdelivery
The NEDAW 2026 Toolkit is designed to help individuals and organizations raise awareness, promote conversations, and support recovery during the observance.
https://womenshealth.gov/sites/default/files/_documents/2026/nedaw/nedaw-2026-factsheet-23JAN26.pdf?utm_medium=email&utm_source=govdelivery
Menopause is a natural part of life that brings changes to your body, emotions, and eating habits.
Hormonal shifts, weight changes, and new challenges during this time may affect how you feel about
your body and lead to or trigger unhealthy eating patterns or eating disorders. Studies show nearly 8%
of women aged 40 and above meet the requirements for an eating disorder.
National Eating Disorders Awareness Week
https://womenshealth.gov/nedaw?utm_medium=email&utm_source=govdelivery
Join us this week in observing National Eating Disorders Awareness Week (NEDAW).
This annual observance highlights the impact of eating disorders across the United States, particularly among women and girls, and uplifts resources and support for individuals, families, and health care providers who provide treatment.
This year’s theme, “Health At Every Age: Eating Disorder Awareness, Prevention, and Recovery,” reinforces the importance of addressing eating disorders at every stage of life and encourages awareness of how eating disorders intersect with aging, hormonal transitions, and chronic disease. By recognizing the connections between eating disorders and chronic conditions such as cardiovascular disease, diabetes, and osteoporosis, this observance supports integrated approaches to prevention and long-term health, empowering women and girls to achieve optimal well-being for themselves, their families, and their communities.
Pet Vaccines: Are They Safe? By Ivanhoe Broadcast News on March 6, 2026
https://www.ivanhoe.com/?p=36764&preview=1&_ppp=ea0c2da112
ORLANDO, Fla. (Ivanhoe Newswire) — About one in six parents in the U.S. have skipped or delayed vaccinating their kids against diseases other than COVID or the flu. Now those same fears over vaccine safety are spreading to pet owners. Many question whether vaccines are safe for their dogs and cats.
Breathing Pain Free After Heart Surgery! By Ivanhoe Broadcast News on March 5, 2026Cardiovascular
https://www.ivanhoe.com/?p=36761&preview=1&_ppp=ce3f8b350e
CLEVELAND, Ohio. (Ivanhoe Newswire) — Imagine your heart not functioning properly and you not knowing for years! That’s the reality of people with aortic valve disease. Symptoms include chest pain, dizziness, fatigue, and irregular heartbeat. If the disease is above a mild or moderate state, the only option has been surgery. But now there’s a new option.
Not Just a Woman’s Disease: Osteoporosis in Men By Ivanhoe Broadcast News on March 4, 2026
https://www.ivanhoe.com/?p=36758&preview=1&_ppp=cf8d6ea8f6
ORLANDO, Fla. (Ivanhoe Newswire) — Approximately 10 million Americans have osteoporosis and another 44 million have low bone density, placing them at increased risk. Yet nearly 80% of older Americans who suffer bone breaks are not tested or treated for osteoporosis. While women have it more often, it’s just as dangerous for men.
Lower Your Skin Cancer Risk! By Ivanhoe Broadcast News on March 3, 2026
https://www.ivanhoe.com/?p=36755&preview=1&_ppp=83f0f998af
ORLANDO, Fla. (Ivanhoe Newswire) — More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined.
Hope Restored: Finding Lorenzo’s Voice By Ivanhoe Broadcast News on March 2, 2026
https://www.ivanhoe.com/?p=36752&preview=1&_ppp=fbf41d3d56
ORLANDO, Fla. (Ivanhoe Newswire) — It’s a rare and devastating disease that can silence a person’s voice and breath, literally! Recurrent respiratory papillomatosis, or RRP, has forced some people to undergo hundreds of surgeries just to breathe or speak again. Now, for the first time ever, the FDA has approved a treatment that targets the root cause of the disease, helping patients find their voice and breathe again.
CLINICAL PERSPECTIVES: Bleximenib Combination Therapy for Patients With Acute Myeloid Leukemia +++++ +++++ +++
CLINICAL PERSPECTIVES
Bleximenib Combination Therapy for Patients With Acute Myeloid Leukemia
https://checkrare.com/bleximenib-combination-therapy-for-patients-with-acute-myeloid-leukemia/
Hartmut Döhner, MD, Professor of Medicine and Medical Director of the Department of Hematology and Oncology, Ulm University, Germany, discusses bleximenib combination therapy for treatment of patients with acute myeloid leukemia (AML).
Rare Diseases in Ireland – New Efforts to Improve Access to Care
https://checkrare.com/rare-diseases-in-ireland-new-efforts-to-improve-access-to-care/
We recently visited Ireland and learned more about the country’s rare disease efforts, which included plans to implement a new national strategy ensuring that people who have rare diseases can quickly gain access to the best possible health care.
A Family’s Experience With Nasopharyngeal Carcinoma
https://checkrare.com/a-familys-experience-with-nasopharyngeal-carcinoma/
Floyd Stewart, patient with stage 4 nasopharyngeal carcinoma, and Monique Stewart, advocate and Floyd’s wife, discuss their family’s experience with the disease and their advocacy work.
Current Trends in the Healthcare Job Market
https://checkrare.com/current-trends-in-the-healthcare-job-market/
Vicki Salemi, Career Expert, discusses current trends in the healthcare job market and expectations for 2026.
Treatment With Elritercept for Patients With Myelofibrosis
https://checkrare.com/treatment-with-elritercept-for-patients-with-myelofibrosis/
Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF).
Updated Phase 2 Results of Telquetamab + Teclistamab in Multiple Myeloma
https://checkrare.com/updated-phase-2-results-of-telquetamab-teclistamab-in-multiple-myeloma/
Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM).
Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma
https://checkrare.com/results-from-the-cartitude-4-clinical-trial-in-multiple-myeloma/
Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM).
Results of Part 1a of the OLYMPIA-3 Study of Odronextamab+Chemotherapy in Diffuse Large B Cell Lymphoma
https://checkrare.com/results-of-part-1a-of-the-olympia-3-study-of-odronextamabchemotherapy-in-diffuse-large-b-cell-lymphoma/
Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).
Ibr+Ven Combination Therapy Versus Clb+Obi Combination Therapy in Chronic Lymphocytic Leukemia
https://checkrare.com/ibrven-combination-therapy-versus-clbobi-combination-therapy-in-chronic-lymphocytic-leukemia/
Paolo Ghia, MD, PhD, Professor of Medical Oncology at the Università Vita-Salute San Raffaele in Milan, Italy, discusses data comparing ibrutinib plus venetoclax combination therapy with chlorambucil + obinutuzumab combination therapy in patients with chronic lymphocytic leukemia (CLL).
Results from the LINKER-MM4 Clinical Trial in Multiple Myeloma
https://checkrare.com/results-from-the-linker-mm4-clinical-trial-in-multiple-myeloma/
Robert Orlowski, MD, PhD, Professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses results from the LINKER-MM4 clinical trial testing Lynozyfic (linvoseltamab) to treat patients with newly diagnosed multiple myeloma (MM).
The cAMeLot-2 Trial Testing Bleximenib Combination Therapy for Acute Myeloid Leukemia
https://checkrare.com/the-camelot-2-trial-testing-bleximenib-combination-therapy-for-acute-myeloid-leukemia/
Elias Jabbour, MD, MD Anderson Cancer Center at the University of Texas, discusses the cAMeLot-2 study design of bleximenib combination therapy for patients with acute myeloid leukemia (AML).
Ongoing Phase 3 Study of Paltusotine in Carcinoid Syndrome Due to Neuroendocrine Tumors
https://checkrare.com/ongoing-phase-3-study-of-paltusotine-in-carcinoid-syndrome-due-to-neuroendocrine-tumors/
Aman Chauhan, MD, Oncologist at the University of Miami, discusses details of a phase 3 study testing paltusotine in patients with carcinoid syndrome due to neuroendocrine tumors (NETs).
Results From the DeFi Clinical Trial of Nirogacestat in Patients With Desmoid Tumors
https://checkrare.com/results-from-the-defi-clinical-trial-of-nirogacestat-in-patients-with-desmoid-tumors/
Bernd Kasper, MD, PhD, University of Heidelberg Cancer Center, discusses results from the DeFi clinical trial of nirogacestat in patients with desmoid tumors.
New Staging Tool Available for Healthcare Providers Treating Patients With CTCL by CheckRare Staff|
New Staging Tool Available for Healthcare Providers Treating Patients With CTCL
by CheckRare Staff|
https://checkrare.com/new-staging-tool-available-for-healthcare-providers-treating-patients-with-ctcl/
viernes, 27 de febrero de 2026
From no options to new hope: How science, partnership and persistence are driving progress towards treatments for CASK 26 February 2026
https://rarerevolutionmagazine.com/from-no-options-to-new-hope-how-science-partnership-and-persistence-are-driving-progress-towards-treatments-for-cask/
SPONSORED CONTENT -THIS ARTICLE HAS BEEN FUNDED AND WRITTEN BY THE OXFORD-HARRINGTON RARE DISEASE CENTRE
Matthew Wood and Matthew P. Anderson of the Oxford-Harrington Rare Disease Centre (OHC) highlight their commitment to driving progress for rare disease—impacting the lives of families like Cynthia Schulz and her daughter Noni who spent decades living without answers or effective treatments for CASK
Written by Matthew Wood, MD, PhD, director and chief scientific officer, and
Matthew P. Anderson, MD, PhD, co-director of the Oxford-Harrington Rare Disease Centre
Managing Diabetes
https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes
Diabetes can affect almost every part of your body, including your heart, eyes, kidneys, and nerves. Diabetes is also linked to some types of cancer. You may be able to prevent or delay diabetes health problems by leading a healthy lifestyle, taking your medicines, and managing your blood glucose level, also called blood sugar level. Work with your health care team to create a diabetes care plan that works for you.
Severe CTE clearly linked to dementia
Severe CTE clearly linked to dementia
At a Glance
Researchers found that severe chronic traumatic encephalopathy (CTE) was strongly associated with dementia and cognitive symptoms.
The study provides the clearest evidence to date of the long-term impact of repeated head injuries on brain health.
https://www.nih.gov/news-events/nih-research-matters/severe-cte-clearly-linked-dementia
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell?utm_medium=email&utm_source=govdelivery
On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Not fighting alone: A Veteran’s journey with VA’s TelePain program February 26, 2026 Kimberly A. Kalista VISN 4 Public Affairs/Outreach Program Manager
https://news.va.gov/145253/not-fighting-alone-journey-telepain-program/
“TelePain led me from silently struggling to shared healing.”
For years after leaving the service, Marine Corps Veteran William Anthony Zullo’s body had become a ledger of old battles—more than 20 surgeries, chronic pain in almost every joint and migraines so fierce they could drop him where he stood. On damp, gray mornings in his Philadelphia neighborhood, even the simplest tasks became obstacles that required the same grit he once used while on deployment.
jueves, 26 de febrero de 2026
I had a brother with schizophrenia. I can’t stop thinking about Nick Reiner’s siblings Those who grow up alongside serious mental illness are too often overlooked
https://www.statnews.com/2026/02/26/nick-reiner-mental-illness-siblings-schizophrenia/
By Debra ManettaFeb. 26, 2026
Manetta is a writer and certified life coach in New Rochelle, N.Y.
Editorial p147 Childhood hypertension: prevention beyond obesity The Lancet Child & Adolescent Health +++ +...
The global need for paediatric palliative care: the evolution of serious health-related suffering in children aged 0–19 years from 1990 to 2023
Julia Downing, PhDa,b,c,* ∙ Prof Felicia Marie Knaul, PhDd,e,f,g,* ∙ Xiaoxiao Jiang Kwete, MBBSd,h ∙ Prof Héctor Arreola-Ornelas, MSce,f,g,i kevin.sheth@yale.edu ∙ Nickhill Bhakta, MDj ∙ William E Rosa, PhDk ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00338-4/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-_HFn6fU22iteg7Gn1sxD8HaBdoDOasNELaGb4nCKsszQB4B_FpQsWIlhO7vKLUOnh2T5-lPcOBBgV4dl1niR4mprrCEw&_hsmi=405655671&utm_content=405653686&utm_source=hs_email
Paracetamol versus ibuprofen as required for fever or pain in the first year of life and the risk of eczema and bronchiolitis at age 1 year in New Zealand (PIPPA Tamariki): a multicentre, open-label, parallel-group, superiority, randomised controlled trial
Eunicia Tan, MBChBa,b ∙ Christopher J D McKinlay, PhDc,d ∙ Judith Riley, PGDipClinRe ∙ Medhawani Rao, PGDipAdvNsgf ∙ Lisa Mravicich, BHScc,g ∙ Shirley Lawrence, BHSch ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00341-4/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-9uS6ZiICK3-PxRXGc-EQCF_7n5RxgaM6GaVu-W_F4_xoNVhGg49Ffec8qORYrBywhK3d-cm-S_zZ3aiAfvFo_MqOga6g&_hsmi=405655671&utm_content=405653686&utm_source=hs_email
Under pressure: the lifelong cardiovascular health of children and youth with primary hypertension
Rahul Chanchlani, MD MSca,b chanchlr@mcmaster.ca ∙ Prof Tammy Brady, MD PhDc ∙ Prof Ruan Kruger, PhDd ∙ Prof Manish D Sinha, MRCP PhD
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00302-5/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-9jCaWjzuMtWtv1ZvWHmpJ44DhQTN1GW4e_vykkTXoyt4OTuqaimaAAKIxHPZgxdIMtwm7wJDKuj0LtipVGLbDg42k76w&_hsmi=405655671&utm_content=405653686&utm_source=hs_email
Editorial
p147
Childhood hypertension: prevention beyond obesity
The Lancet Child & Adolescent Health
https://www.thelancet.com/journals/lanchi/issue/vol10no3/PIIS2352-4642(26)X2001-6
Comment Oral GLP-1 receptor agonists: competition for efficacy and tolerability Michael A Nauck,Michael Horowitz +++... +
Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
Prof Chloe Orkin, MDa c.m.orkin@qmul.ac.uk ∙ Peter J Ruane, MDb ∙ Malcolm Hedgcock, MDc ∙ Cyril Gaultier, MDd ∙ Prof Marcelo H Losso, MDe,f ∙ Benoit Trottier, MDg ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00307-7/fulltext?dgcid=hubspot_email_conferencealerts_croi26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-91M5bhF5qzAqzlaqFCPWtsfvPvo3OXkzrQ2ujxeTpEJuZ2HYDhk6ftmaZC-GslqKwleAYDNVBsGTZMVWdrxkSE5IwRww&_hsmi=405519679&utm_content=405519679&utm_source=hs_email
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Prof Jürgen K Rockstroh, MDa ∙ Sheetal Kassim, MDb ∙ Roger Paredes, PhDc,d,e ∙ Christopher Bettacchi, MDf ∙ Gary Sinclair, MDg ∙ Anchalee Avihingsanon, MDh ∙ et al.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00033-0/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_croi26&_hsenc=p2ANqtz--VPAxr8fcBTG4bnoCELgBXznyfyCBCq2XDdf7bx-_EVkKwdFTkxI7QCvODcHj9yfqsLIXg8U4P1B0IAyF8rPPfHoXAOw&_hsmi=405519679&utm_content=405519679&utm_source=hs_email
Comment
Oral GLP-1 receptor agonists: competition for efficacy and tolerability
Michael A Nauck,Michael Horowitz
https://www.thelancet.com/journals/lancet/onlinefirst
Managing complex antiretroviral regimens
Michael S Saag
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00364-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_croi26&_hsenc=p2ANqtz-9S-JImB9lO5qo_6WfA1WG_M_aqHSHIh9NNEpfQN9qN1_GnoE665ALe-TbY5fNM5Dr-fDbfMLL-j1TNzHdmBfFvq3uuHg&_hsmi=405519679&utm_content=405519679&utm_source=hs_email
How evidence and patient realities can help us to rethink the future of MG care 25 February 2026 By Anna Kole (UCB) with the Rethinking MG project partners, Lutgarde Allard (EuMGA), Giuseppe Turchetti (SSSA) and Vinciane Quoidbach (EBC)
https://rarerevolutionmagazine.com/how-evidence-and-patient-realities-can-help-us-to-rethink-the-future-of-mg-care/
“As a teenager, I sometimes imagined I would grow up to be a mother. It was at least an option that I hoped would be open to me. But living with MG has changed what’s possible. Some days, taking care of myself is already more than I can manage, and I’ve had to accept that motherhood may not be in reach for me. It’s a small, unseen sacrifice, but some days it really gets to me.”
Promises and challenges of AI in infectious diseases The Lancet Infectious Diseases ++... ++
Promises and challenges of AI in infectious diseases
The Lancet Infectious Diseases
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00078-2/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 26Number 3p213-328, e132-e208
https://www.thelancet.com/journals/laninf/issue/vol26no3/PIIS1473-3099(26)X2002-3
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
Alex Howard, MBChBa,b Alexander.Howard@liverpool.ac.uk ∙ Nada Reza, MBChBa,b ∙ Peter L Green, PhDc ∙ Mo Yin, DPhild,e,f,g ∙ Erin Duffy, PhDh ∙ Prof Henry C Mwandumba, PhDi,j ∙ et al.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00313-5/abstract?dgcid=raven_jbs_etoc_feature_laninf
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
GBD 2023 Chagas Disease and RAISE Study Collaborators*
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00562-6/abstract?dgcid=raven_jbs_etoc_feature_laninf
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations. The guidelines were updated to comply with Executive Orders.
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new
Why All Mammograms Should Incorporate AI Eric J. Topol, MD February 25, 2026 +++ +++
Why All Mammograms Should Incorporate AI
Eric J. Topol, MD
https://www.medscape.com/s/viewarticle/why-all-mammograms-should-incorporate-ai-2026a1000569?ecd=wnl_edit_tpal_etid8138104&uac=148436CN&impID=8138104
February 25, 2026
How Nighttime Light Quietly Became a Serious Health Threat
Nicole Pajer
https://www.medscape.com/viewarticle/how-nighttime-light-quietly-became-serious-health-threat-2026a10005w7?ecd=wnl_edit_tpal_etid8138104&uac=148436CN&impID=8138104
February 25, 2026
Hospital-Treated Infections Linked to Decade-Long Increase in IBD Risk
Becky McCall, PhD, MScPh
https://www.medscape.com/viewarticle/hospital-treated-infections-linked-decade-long-increase-ibd-2026a10005wy?ecd=wnl_edit_tpal_etid8138104&uac=148436CN&impID=8138104
February 25, 2026
Q&A: AMA President’s Health Crisis Informs View of US System
Randy Dotinga
https://www.medscape.com/viewarticle/q-ama-presidents-health-crisis-informs-view-us-system-2026a10005xp?ecd=wnl_edit_tpal_etid8138104&uac=148436CN&impID=8138104
February 25, 2026
Which Drugs Turn Risky When Temperatures Soar?
Manuela Callari
https://www.medscape.com/viewarticle/which-drugs-turn-risky-when-temperatures-soar-2026a10005vc?ecd=wnl_edit_tpal_etid8138104&uac=148436CN&impID=8138104
Medscape Europe
February 24, 2026
Molluscum: A Pediatric Dermatologist’s Recommendations for Treatment and Counseling Parents
Christine Kilgore
https://www.medscape.com/viewarticle/molluscum-pediatric-dermatologists-recommendations-treatment-2026a10005wh?ecd=wnl_edit_tpal_etid8138104&uac=148436CN&impID=8138104
February 25, 2026
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D) CDER’s ARC Program | Center for Drug Evaluation and Research +++
https://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/learning-and-education-advance-and-empower-rare-disease-drug-developers-leader-3d?utm_medium=email&utm_source=govdelivery
Opportunity for Public Comment on Rare Disease Educational Materials from the Center for Drug Evaluation and Research’s Accelerating Rare disease Cures Program and the Rare Disease Innovation Hub
Posted by the Food and Drug Administration on Feb 11, 2026
https://www.regulations.gov/document/FDA-2026-N-1584-0001?utm_medium=email&utm_source=govdelivery
FDA Rare Disease Innovation Hub
https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub?utm_medium=email&utm_source=govdelivery
What is the newest evidence about PCSK9 inhibitors? (Medscape AI) +++ +++
What is the newest evidence about PCSK9 inhibitors?
https://www.medscape.com/ai-search?query=What%20is%20the%20newest%20evidence%20about%20PCSK9%20inhibitors%3F&&ecd=mkm_ret_260226_mscpmrk-OUS_DisReferences_etid8129601&uac=148436CN&impID=8129601
When to evaluate calprotectin in children with ulcerative colitis (Medscape AI)
https://www.medscape.com/ai-search?query=When%20to%20evaluate%20calprotectin%20in%20children%20with%20ulcerative%20colitis&&ecd=mkm_ret_260226_mscpmrk-OUS_DisReferences_etid8129601&uac=148436CN&impID=8129601
What are common drug-drug interactions between amiodarone and standard heart failure medications (Medscape AI)
https://www.medscape.com/ai-search?query=What%20are%20common%20drug-drug%20interactions%20between%20amiodarone%20and%20standard%20heart%20failure%20medications&&ecd=mkm_ret_260226_mscpmrk-OUS_DisReferences_etid8129601&uac=148436CN&impID=8129601
Escalation and De-Escalation of Therapy
Fast Five Quiz: Escalation and De-Escalation of Therapy in Early Breast Cancer
Reviewed by Maurie Markman, MD
February 17, 2026
https://reference.medscape.com/viewarticle/early-bc-de-escalation-and-escalation-therapy-2026a10000a4?ecd=mkm_ret_260226_mscpmrk-OUS_DisReferences_etid8129601&uac=148436CN&impID=8129601
Obesity-Related Hypertension
Fast Five Quiz: Obesity-Related Hypertension
Yasmine S. Ali, MD
https://reference.medscape.com/viewarticle/fast-five-quiz-obesity-related-hypertension-2025a1000e9q?ecd=mkm_ret_260226_mscpmrk-OUS_DisReferences_etid8129601&uac=148436CN&impID=8129601
A Nonsmoker With a Persistent Stubborn Cough
A Nonsmoker With a Persistent Stubborn Cough
Juan Antequera Martin-Portugués, DO
https://reference.medscape.com/viewarticle/nonsmoker-persistent-stubborn-cough-2026a10004fp?ecd=mkm_ret_260226_mscpmrk-OUS_DisReferences_etid8129601&uac=148436CN&impID=8129601
Rapid Review Quiz: Plant-based Diets Romesh Khardori, MD, PhD February 12, 2026 ++++
Rapid Review Quiz: Plant-based Diets
Romesh Khardori, MD, PhD
February 12, 2026
https://reference.medscape.com/viewarticle/rapid-review-quiz-plant-based-diets-2026a100031s?ecd=WNL_rrq_260226_MSCPEDIT_etid8135912&uac=148436CN&impID=8135912
Rapid Review Quiz: Artificial Sweeteners
Reviewed by John Birk, MD
October 07, 2025
https://reference.medscape.com/viewarticle/rapid-review-quiz-artificial-sweeteners-2025a1000p26?ecd=WNL_rrq_260226_MSCPEDIT_etid8135912&uac=148436CN&impID=8135912
Rapid Rx Quiz: New Insights into GLP-1 RAs
Mary L. Windle, PharmD
September 05, 2025
https://reference.medscape.com/viewarticle/rapid-rx-quiz-glp-1-ras-2025a1000m26?ecd=WNL_rrq_260226_MSCPEDIT_etid8135912&uac=148436CN&impID=8135912
Rapid Review Quiz: Intermittent Fasting
Romesh Khardori, MD, PhD
September 05, 2025
https://reference.medscape.com/viewarticle/rapid-review-quiz-intermittent-fasting-2025a1000ltz?ecd=WNL_rrq_260226_MSCPEDIT_etid8135912&uac=148436CN&impID=8135912
miércoles, 25 de febrero de 2026
Scientists uncover nanoplastics in brain tissue and question their role in neurological disease
https://www.news-medical.net/news/20260217/Scientists-uncover-nanoplastics-in-brain-tissue-and-question-their-role-in-neurological-disease.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_24_february_2026
Scientists are detecting nanoplastics in human brain tissue and exploring how these particles may influence the risk of neurodegenerative diseases, but major questions about exposure, causation, and prevention remain unresolved.
Muscles retain molecular memory of repeated inactivity
https://www.news-medical.net/news/20260225/Muscles-retain-molecular-memory-of-repeated-inactivity.aspx
Muscle loss, or atrophy, due to inactivity is common after illness, injury, hospitalization or falls, and becomes increasingly frequent with aging. New research published in Advanced Science shows that skeletal muscle retains a "molecular memory" of repeated disuse-and that this memory differs markedly between young and old muscles.
Opioids offer limited short-term relief for acute pain
https://www.news-medical.net/news/20260225/Opioids-offer-limited-short-term-relief-for-acute-pain.aspx
The world's largest review of opioid pain relievers prescribed for acute pain found these medicines provide only small, short-term relief for some acute conditions and are ineffective for some others.
No evidence connects tick bites to chronic health problems
https://www.news-medical.net/news/20260225/No-evidence-connects-tick-bites-to-chronic-health-problems.aspx
When researchers studied Norwegians who thought tick bites caused their chronic health problems, they found no objective evidence linking the symptoms to ticks.
Duckweed Protein Benefits: Is This Aquatic Plant a Sustainable Superfood?
https://www.news-medical.net/health/Duckweed-Protein-Benefits-Is-This-Aquatic-Plant-a-Sustainable-Superfood.aspx
A fast-growing aquatic plant may offer a high-quality, bioavailable protein alternative, yet its safety profile and mineral variability could determine whether duckweed becomes a future staple or remains a niche innovation.
Using Artificial Intelligence to Predict Chronic Disease Through Diet and Multi-Omics Data
https://www.news-medical.net/health/Using-Artificial-Intelligence-to-Predict-Chronic-Disease-Through-Diet-and-Multi-Omics-Data.aspx
This article explains how artificial intelligence integrates nutritional data, machine learning, and multi-omics to improve the prediction of diet–disease relationships while emphasizing the need for validation, transparency, and clinical oversight. It highlights emerging clinical applications in chronic disease alongside methodological limits in measurement, causality, and ethical implementation.
NIH-supported trial reduces HIV incidence by 70% in rural populations Study used technology to extend reach of existing infrastructure, linking people to care.
https://www.nih.gov/news-events/news-releases/nih-supported-trial-reduces-hiv-incidence-70-rural-populations
A study funded by the National Institutes of Health (NIH) reduced new HIV cases by 70% in rural Kenya and Uganda by pairing digital tools with tailored HIV services delivered by community health workers and clinicians. This successful strategic implementation of existing healthcare infrastructure and available HIV prevention and treatment options could become a model for reducing HIV incidence in other countries, including the United States. The findings were presented today at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver.
Manipulating gene activity to reverse aging
Manipulating gene activity to reverse aging
At a Glance
Altering levels of certain molecules called transcription factors reversed some of the effects of aging in mice.
The findings show the potential of targeting transcription factors to counter age-related illnesses
https://www.nih.gov/news-events/nih-research-matters/manipulating-gene-activity-reverse-aging
Severe CTE clearly linked to dementia
Severe CTE clearly linked to dementia
https://www.nih.gov/news-events/nih-research-matters/severe-cte-clearly-linked-dementia
At a Glance
Researchers found that severe chronic traumatic encephalopathy (CTE) was strongly associated with dementia and cognitive symptoms.
The study provides the clearest evidence to date of the long-term impact of repeated head injuries on brain health.
Progress toward a blood test for early pancreatic cancer
Progress toward a blood test for early pancreatic cancer
https://www.nih.gov/news-events/nih-research-matters/progress-toward-blood-test-early-pancreatic-cancer
At a Glance
Researchers identified markers in blood that could be used to identify people with pancreatic cancer at earlier stages when it is more treatable.
A blood test that could detect pancreatic cancer before it has spread to other parts of the body could help improve survival.
We're here to make clinical trials clear and accessible for people living with a condition.
https://trialport.com/
You are not alone
Written by Keith Berlowitz, pRxTrialPort
Exploring how family and friends quietly shape health decisions, emotional resilience and participation in clinical research through care, trust and everyday support
Family and friends, the quiet influence
A rare diagnosis doesn’t just change a life. It changes the entire rhythm of a home. Rare disease creates an invisible shift. Roles change overnight. Family and friends become the unofficial care team, providing support in a number of ways, emotional, admin, advocacy, logistics and filling many other roles. Parents become care coordinators. Partners become protectors and planners. Siblings become early caregivers, sometimes without anyone realising it. True friends become closer than family while others disappear completely. Rare disease doesn’t just happen to one person. It happens to a whole family and often encompasses the wider circle of a person’s whole community.
The diagnosis moment is a before-and-after event for everyone. Even when families feel relieved to finally “have a name for it,” diagnosis often brings many different emotions. Families carry grief, fear and the guilt of “did I miss something?” They feel uncertainty for the future and financial anxiety. They want to provide their loved one with the best care and treatment possible, but they have no idea where to start. The family isn’t just learning a condition; they’re learning a new life.
After diagnosis, the work begins. For many people I have spoken to and for ourselves following my daughter's diagnosis, it was a google search, followed by accessing support groups to learn more. Whilst my daughter’s condition is mild, for many others I have spoken with, caring for their loved one often becomes like a second job because of the combination of the emotional load and the admin load that they willingly take on. Families don’t just support emotionally, they carry a massive invisible workload. Appointments mean taking time off work, finding childcare, travelling and the expenses that go along with it. They sift through insurance paperwork and navigate hospital appointments. They create caregiving schedules, manage information overload and are forced to quickly learn all kinds of medical terminology. This is not only caregiving. It is project management under stress.
Connection matters: community reduces isolation
My experience within varying rare disease communities has shown me that the mental health impact spreads through the family circle. Rare disease stress doesn’t stay contained. Family members and friends can experience chronic anxiety, burnout, relationship strain, loneliness and anticipatory grief. Many supporters feel they must stay strong and don’t ask for support themselves. Supporting the supporters is not optional; it’s part of good care.
A diagnosis can be devastating, but it can also become the moment where people re-organise around love, purpose and problem-solving. Families are asked to bear a heavy load, but through it all, many choose to grow stronger, closer together and become a superpower. They often evolve into advocates, educators, fundraisers, organisers and community builders. Rare disease communities are among the strongest examples of human resilience and collective intelligence. Families do not choose this path, but they can choose how they walk it: together.
One of the biggest harms of rare disease is isolation. Community brings many things to its members: understanding without explanation, shared practical tips, emotional relief, shared language and much more.
Rare Disease Day is observed on the last day of February to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. The date was chosen because in leap years it is February 29, the rarest date. Rare Disease Day is an anchor moment to remind people: “You are not alone.” “Your experience is valid.” “Help exists, even when answers are incomplete.”
Clinical research brings hope
Many families want to do something, not just cope. Clinical research can offer potential access to investigational therapies, progress for the community and meaning and agency, yet the process can be confusing when it is layered on the existing emotional load. As an industry we do not always make it easy to find trials. Trial eligibility is difficult to understand and many times it’s unclear what participation really involves.
When clinical research exists, families should be able to find it easily and understand it clearly. Platforms like pRxTrialPort are built to support that journey, helping people explore options without pressure and with clarity at the centre. At pRxEngage Inc (the company behind the platform) we strongly believe trials are one of many options and families deserve decision support, not pressure. The platform’s primary goal is to give back agency and to help families move from overwhelm to clarity to informed choice.
If you or someone you love is navigating a rare disease and wants to explore what research options may exist, take a moment to look. Not to commit. Not to decide. Just to understand. Clarity is often the first step toward feeling less alone.
The rare disease journey is deeply personal, but it should never feel lonely. This Rare Disease Day, check in on someone living with a rare disease. Ask them “How are you really?” and listen on purpose. Offer practical help for rides, meals or other admin tasks. Just being there for them can make a huge impact.
Social media ban: a band-aid on digital wounds? The Lancet Public Health ++... ++
Social media ban: a band-aid on digital wounds?
The Lancet Public Health
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00024-1/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 11Number 3e137-e201
https://www.thelancet.com/journals/lanpub/issue/vol11no3/PIIS2468-2667(26)X2002-3
Accelerating cervical cancer elimination in Aboriginal and Torres Strait Islander women: a modelling study
Megan A Smith, PhDa megan.smith@sydney.edu.au ∙ James Killen, BEnga ∙ Prof Lisa Jamieson, PhDb ∙ Xavier O'Farrell, MDa ∙ Diep T N Nguyen, PhDa ∙ Prof Gail Garvey, PhDc,* ∙ et al.
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00005-8/fulltext?dgcid=raven_jbs_etoc_feature_lanpub
The Lancet Summit: shaping the future of diabetes prevention
Nov 30–Dec 2, 2026 | Sitges, Spain
https://thelancetsummit.com/diabetes-prevention/index.html
How dentists like me can help patients with substance use disorder Dental professionals have a rare opportunity to spot signs of addiction
https://www.statnews.com/2026/02/25/dentists-substance-use-disorder-screening-opioids/
By Divya UpadhyayFeb. 25, 2026
Upadhyay is a dentist practicing in the Greater Boston area.
6 in 10 women will develop heart disease or stroke by 2050, heart association projects Rising obesity among girls means heart disease will arrive sooner: ‘It’s alarming’
https://www.statnews.com/2026/02/25/heart-disease-risk-forecasts-women-2050-projections/
By Elizabeth CooneyFeb. 25, 2026
Cardiovascular Disease Reporter
FDA Approves Drug for Adult and Pediatric Patients Aged 6 and Older with Allergic Fungal Rhinosinusitis
FDA Approves Drug for Adult and Pediatric Patients Aged 6 and Older with Allergic Fungal Rhinosinusitis
On February 23, 2026, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) with a history of sino-nasal surgery or for whom surgery is not advisable. This is the first approval for this condition.
Condition
Allergic fungal rhinosinusitis (AFRS) is an uncommon type of chronic sinus inflammation caused by an allergic reaction to fungi growing in the sinuses, with production of thick, sticky mucus often described as resembling peanut butter. AFRS affects up to 8% of people with chronic sinus inflammation and nasal polyps, is more common in warm, humid areas where fungi thrive, and typically begins in teenagers and young adults. If left untreated, AFRS can cause serious problems, including expansion of the sinuses, erosion of surrounding bone (in up to 90% of patients), and spread to the eye area or brain, leading to facial deformities, vision problems, and nerve damage.
Data Supporting Dupixent
Dupilumab's effectiveness and safety were evaluated in a 52-week study of adult and pediatric participants aged 6 years and older with AFRS. The study showed that dupilumab significantly improved sinus opacification compared to placebo, as measured by CT scan scores (Lund-Mackay score). Additional measures — including nasal polyp size, nasal congestion, and sense of smell — also showed significant improvement and supported the main findings.
Dupilumab substantially reduced the need for systemic corticosteroids and sinus surgery compared to placebo over 52 weeks, which is particularly important given the severity of AFRS. The medication also reduced sinus bone erosion, a serious complication unique to AFRS. Together, these results demonstrate clear benefits across imaging findings, endoscopic results, and patient-reported symptoms.
The safety profile of dupilumab in AFRS patients is similar to what has been observed in patients with chronic rhinosinusitis with nasal polyps, both in clinical trials and post-market setting. No safety issues were identified that would outweigh the benefits of dupilumab.
For children and adolescents aged 6 to <18 years, the effectiveness of dupilumab is based on adult AFRS data, supported by the fact that the disease works similarly across age groups and that children achieve comparable drug levels at weight-adjusted doses. Safety data comes from supportive results in children and adolescents treated for other conditions.
Based on the trial results and the existing safety database for dupilumab's approved uses, the benefits outweigh the risks for treating AFRS in patients 6 years and older.
Safety Information
The most common side effects of Dupixent are injection-site reactions, eosinophilia (elevated count of white blood cells), insomnia, toothache, gastritis, and joint pain.
Designation
Dupixent received priority review designation for this indication.
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation?utm_medium=email&utm_source=govdelivery
On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
martes, 24 de febrero de 2026
NUS scientists transform kombu into a probiotic superfood with fruity aromas
https://www.news-medical.net/condition/Functional-Food
This hub provides a comprehensive overview and the latest news on functional foods, superfoods, and dietary components that contribute to health and disease prevention. The collection highlights bioactive compounds in foods such as lychee, chia seeds, dates, baobab fruit, and black sesame, alongside evidence-based discussions on fermented foods, postbiotics, and algae-based supplements. Readers will also find insights into the health benefits of traditional and modern diets, including the Atlantic and Washoku patterns, as well as functional beverages and plant-derived oils. By combining nutritional science, clinical research, and updates on emerging food innovations, this hub equips healthcare professionals, researchers, and health-conscious individuals with reliable knowledge to evaluate functional foods and their role in supporting long-term wellness.
Digital Twins in Precision Medicine and Drug Discovery
https://www.news-medical.net/life-sciences/Digital-Twins-in-Precision-Medicine-and-Drug-Discovery.aspx
Digital twins introduce a shift from static, retrospective modeling to continuously learning systems that adapt as new biological and clinical evidence emerges. By linking mechanistic understanding with artificial intelligence (AI)-driven prediction, they enable earlier failure detection, smarter trial design, and more confident decision-making across the drug development lifecycle.
Moments of awe show measurable links to reduced loneliness in daily life
https://www.news-medical.net/news/20260223/Moments-of-awe-show-measurable-links-to-reduced-loneliness-in-daily-life.aspx
New longitudinal evidence suggests that moments of awe, even during pandemic isolation, may help buffer loneliness by strengthening feelings of connection beyond the self.
Swiss centenarians show youthful blood protein profiles in aging study
https://www.news-medical.net/news/20260224/Swiss-centenarians-show-youthful-blood-protein-profiles-in-aging-study.aspx
In Switzerland, 0.02% of the population lives beyond the age of 100. Could there be biological characteristics associated with this exceptional longevity? As part of the "SWISS100" study, the first large-scale Swiss research project dedicated to centenarians, a team from the University of Geneva (UNIGE) and the University of Lausanne (UNIL) compared the blood profiles of centenarians with those of octogenarians, and then with those of individuals aged 30 to 60. Across 37 proteins, centenarians show profiles surprisingly close to those of younger individuals, particularly with remarkably low oxidative stress markers. Among the other proteins identified, at least three are involved in the regulation of the extracellular matrix (the "cement" of our body). Others could play a protective role against tumor development or be involved in lipid and glucose metabolism. These findings are published in the journal Aging Cell.
Indoor plants help create healthier, more climate-resilient buildings
https://www.news-medical.net/news/20260224/Indoor-plants-help-create-healthier-more-climate-resilient-buildings.aspx
Houseplants and more advanced plant systems, such as indoor living walls and hydroponic towers, have the potential to raise indoor humidity, boost thermal comfort and help create healthier, more climate-resilient buildings, according to new research led by the University of Surrey's Global Centre for Clean Air Research (GCARE).
Child stunting: Historical evidence confirms global eradication is possible
https://www.news-medical.net/news/20260224/Child-stunting-Historical-evidence-confirms-global-eradication-is-possible.aspx
New research led by LSE reveals that high‑income countries once suffered severe child stunting comparable to rates seen in many low‑ and middle‑income countries today, offering powerful evidence that child stunting can be eliminated globally.
Five drug approvals to watch in 2026 These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.
https://www.drugdiscoverynews.com/five-drug-approvals-to-watch-in-2026-16982?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_tFN88dAIbLCv9kT2L5vEoNEwvW15zK9GNn4176MSmvT8ho6_7gyP-JCBqff-ZQIF5sk4IScdWOwYVET-Z03m0SfDRWQ&_hsmi=405284917&utm_content=405284917&utm_source=hs_email
During 2025, the FDA approved several notable new drugs and vaccines — from a novel eye drop treatment to the first new oral antibiotic class for uncomplicated urinary tract infections in decades. And looking ahead to 2026, there are several other innovative ‘firsts’ on the way that could reshape how patients manage everything from allergic reactions to diabetes and hypertension.
The Science of Appetite Control: How Hormones Regulate Hunger and Satiety +++
The Science of Appetite Control: How Hormones Regulate Hunger and Satiety
https://www.news-medical.net/health/The-Science-of-Appetite-Control-How-Hormones-Regulate-Hunger-and-Satiety.aspx
This article explains how dietary protein, carbohydrates, fats, and different types of fiber influence key appetite-regulating hormones, including GLP-1, PYY, ghrelin, CCK, and leptin. Drawing from controlled human trials and mechanistic research, it clarifies how nutrient composition affects satiety signaling, energy balance, and weight regulation through the gut–brain axis.
How Different Types of Fiber Improve Blood Sugar Control and Metabolic Health
https://www.news-medical.net/health/How-Different-Types-of-Fiber-Improve-Blood-Sugar-Control-and-Metabolic-Health.aspx
Dietary fiber influences metabolic health through viscosity-driven glycemic control and microbiome-mediated fermentation, with effects that vary by fiber type, metabolic phenotype, and gut microbial composition. evidence from mechanistic studies and large clinical trials shows that fiber’s benefits are real but heterogeneous, supporting a more personalized approach to dietary guidance.
Can Climate-Resilient Crops Improve Human Nutrition?
https://www.news-medical.net/health/Can-Climate-Resilient-Crops-Improve-Human-Nutrition.aspx
As climate change reshapes global agriculture, emerging evidence reveals that pairing stress-tolerant crops with biofortification may be key to safeguarding both harvests and human nutrition.
Editorial focus eBook - Peptides and oligonucleotides (1st edition)
https://www.news-medical.net/industry-focus/Editorial-focus-eBook--Peptides-and-oligonucleotides-(1st-edition)?utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=biochemistry_newsletter_24_february_2026
Our Peptide and Oligonucleotide Editorial Focus eBook offers a curated collection of forward-thinking research, expert commentary, and clinical developments that are reshaping the way targeted therapies are designed, delivered, and manufactured.
How can AI amplify patient voices to improve rare disease communications? 24 February 2026
https://rarerevolutionmagazine.com/how-can-ai-amplify-patient-voices-to-improve-rare-disease-communications/
Written by Claire Inness, scientific services lead, Kristie Marchant, account lead, Meghan Reilly, senior medical writer and Puneet Garcha, account manager, Amiculum
Claire Inness, Kristie Marchant, Meghan Reilly and Puneet Garcha are team members from Amiculum, a global independent healthcare consulting and communications agency. They bring extensive experience in healthcare communications, including significant work in rare disease therapy areas. Their combined expertise spans scientific content development, account leadership and strategic services, enabling the delivery of clear, impactful communications for diverse healthcare audiences
Rare diseases affect millions worldwide, but each only impacts a tiny percentage of the population. Resources are limited, information fragmented and the pathway to diagnosis is long. For patients and their families, navigating this landscape can feel isolating and overwhelming. Artificial intelligence (AI) gives us the opportunity to change this, not only providing patients with scientifically accurate and credible information but tailoring that information specifically for them.
Forging ahead on fibromyalgia The Lancet Rheumatology ++... ++
Forging ahead on fibromyalgia
The Lancet Rheumatology
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00051-2/fulltext?dgcid=raven_jbs_etoc_email
Mar 2026
Volume 8Number 3e159-e232
https://www.thelancet.com/journals/lanrhe/issue/vol8no3/PIIS2665-9913(26)X2002-1
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries
Eleana Bolla, MDa ∙ Anne Grete Semb, MDb ∙ Prof Michelle Petri, MDc ∙ Prof Petros P Sfikakis, MDa ∙ Bahar Artim-Esen, MDd ∙ Gabriela Hernandez-Molina, MDe ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00257-7/abstract?dgcid=raven_jbs_etoc_feature_lanrhe
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial
Prof Andrew P Cope, MDa andrew.cope@kcl.ac.uk ∙ Marianna Jasenecova, MSca ∙ Joana C Vasconcelos, MScb ∙ Sumera Qureshi, MDa ∙ Dr Karin A van Schie, PhDm ∙ Prof Andrew Filer, MDd ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00371-6/fulltext?dgcid=raven_jbs_etoc_feature_lanrhe
New treatment approach could give IBD patients hope, and be a bonanza for drugmakers Combination therapies may transform care for inflammatory bowel disease, but questions linger
https://www.statnews.com/2026/02/24/ibd-combination-therapy-race-abbvie-lilly-pfizer-merck-jnj/
By Allison DeAngelisFeb. 24, 2026
Biotech Startups and Venture Capital Reporter
Targeting PRMT5: A Novel Way to Conquer MTAP-Deleted Unresectable/Metastatic Solid Tumors Dr Pasi Jänne, Dr Konstantinos Leventakos
https://www.medscape.com/viewarticle/1002167?src=0_nl_sms_0&uac=148436CN
In this video, Drs Pasi Jänne (Dana-Farber Cancer Institute) and Konstantinos Leventakos (Mayo Clinic, Minnesota) address key clinical questions, including:
• What is MTAP deletion and how does it create a dependency on PRMT5?
• How do MTA-cooperative PRMT5 inhibitors work to exploit MTAP deletion?
• What do current trials reveal about the efficacy and safety of MTA-cooperative PRMT5is?
Debate Builds Over State’s Plan for Robots in OB Care +++ +++ +++ +++
LATEST NEWS
Debate Builds Over State’s Plan for Robots in OB Care
Alabama’s ‘Pretty Cool’ Plan for Robots in Maternity Care Sparks Debate
Sarah Jane Tribble
https://www.medscape.com/s/viewarticle/alabamas-pretty-cool-plan-robots-maternity-care-sparks-2026a10004rz?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 16, 2026
Preeclampsia Prevention Method Questioned
Preeclampsia Prevention Strategy Falls Short in Large Swedish Population Study
Edited by Lora McGlade
https://www.medscape.com/viewarticle/preeclampsia-prevention-strategy-falls-short-large-swedish-2026a10003if?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 13, 2026
Menstrual Blood Rivals Cervical HPV Testing
Menstrual Blood a High-Sensitivity Screening Option for HPV
Isha Ishtiaq
https://www.medscape.com/viewarticle/menstrual-blood-high-sensitivity-screening-option-hpv-2026a10004h1?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 12, 2026
Hepatitis B Vaccine: 4 Things You May Not Know
Hepatitis B Vaccine: 4 Things You May Not Know
David Warmflash, MD
https://www.medscape.com/viewarticle/hepatitis-b-vaccine-4-things-you-may-not-know-2026a10003iq?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 04, 2026
Maternal Diabetes Tied to Epilepsy Risk in Children
Diabetes in Mothers Tied to Epilepsy Risk in Offspring
Diana Swift
https://www.medscape.com/viewarticle/diabetes-mothers-tied-epilepsy-risk-offspring-2026a10004w3?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 17, 2026
Outsmart Ovarian Cancer With One Surgery
How to Outsmart Ovarian Cancer With One Surgery
Megan Brooks
https://www.medscape.com/viewarticle/how-outsmart-ovarian-cancer-one-surgery-2026a10004hn?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 12, 2026
MENOPAUSE
GSM: Nonhormonal Option Safely Treats Symptoms
Nonablative Radiofrequency Therapy Shows Promise for Postmenopausal Sexual Function
Edited by Lora McGlade
https://www.medscape.com/viewarticle/nonablative-radiofrequency-therapy-shows-promise-2026a10004kg?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 12, 2026
Menopause Alters Body Composition — Even at Normal BMI
Menopause Status Alters Body Composition Across BMI Levels
Edited by Vinod Rane, BS Pharm
https://www.medscape.com/viewarticle/menopause-status-alters-body-composition-across-bmi-levels-2026a100021c?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
Medscape UK
January 27, 2026
HIV & Menopause: A Combo We’re Just Beginning to Understand
HIV and Menopause: A Combo We’re Just Beginning to Understand
Lisa O’Mary
https://www.medscape.com/viewarticle/hiv-and-menopause-combo-were-just-beginning-understand-2026a10004tn?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
February 16, 2026
US DRUG SPOTLIGHT
Mirvetuximab soravtansine
https://reference.medscape.com/drug/elahere-mirvetuximab-soravtansine-4000302?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
Doxorubicin liposomal
https://reference.medscape.com/drug/doxorubicin-liposomal-342121?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
Tisotumab vedotin
https://reference.medscape.com/drug/tivdak-tisotumab-vedotin-4000217?ecd=mkm_ret_260223_mscpmrk_obgyn_latest-news_etid8126908&uac=148436CN&impID=8126908
What Are The Most Common Presenting Symptoms of Crohns Disease (Medscape AI) ++++ ++ +
Fasting Improves Crohn’s Disease Symptoms and Overweight
Kate Johnson
https://www.medscape.com/viewarticle/fasting-improves-crohns-disease-symptoms-and-overweight-2026a10004s5?ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
Medscape Canada
February 16, 2026
Managing GI Complications in Ulcerative Colitis
Jordan E. Axelrad, MD, MPH
https://www.medscape.com/viewarticle/managing-gi-complications-ulcerative-colitis-2026a10003uy?ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
February 17, 2026
Advanced Therapies Show Similar Safety in Crohn’s Disease Treatment
Edited by Shrabasti Bhattacharya
https://www.medscape.com/viewarticle/advanced-therapies-show-similar-safety-crohns-disease-2026a10004n2?ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
February 13, 2026
Diet Patterns May Shape Microbial Diversity and Inflammation Differently in IBD Subtypes
Edited by Manasi Talwadekar
https://www.medscape.com/viewarticle/diet-patterns-may-shape-microbial-diversity-and-inflammation-2026a1000243?ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
Fast Five Quiz: Identify and Treat Crohn's Disease
Reviewed by John W. Birk, MD
https://reference.medscape.com/viewarticle/fast-five-quiz-identify-and-treat-crohns-disease-2025a1000ec7?ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
Fast Five Quiz: Crohn's Disease Management
Reviewed by John W. Birk, MD
https://reference.medscape.com/viewarticle/fast-five-quiz-management-crohn-disease-2025a1000e4b?ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
January 22, 2026
What Are The Most Common Presenting Symptoms of Crohns Disease (Medscape AI)
https://www.medscape.com/ai-search?query=What%20Are%20The%20Most%20Common%20Presenting%20Symptoms%20of%20Crohns%20Disease&&ecd=mkm_ret_260224_mscpmrk-OUS_InFocus_etid8120084&uac=148436CN&impID=8120084
A new destination for open access research in medical imaging and theranostics
https://www.thelancet.com/medical-imaging-theranostics?dgcid=hubspot_email_awa26_lanmitlaunch&utm_campaign=36971128-lanmitlaunch&utm_medium=email&utm_content=404689188&utm_source=hs_email&_hsmi=405070202&_hsenc=p2ANqtz-8cKaDZlfuuSfLVPtKmSnh-mYGCswDRZGkBWz8fG4EAwRaOwfen_8CQ-Y4Z6PsyMuHLX8QcEXKqwhpCTBq-5VBAjrD0zA&hsCtaAttrib=207743325534
The Lancet Medical Imaging & Theranostics will publish clinical research and thought leadership on established or emerging diagnostic imaging and interventional radiology techniques (including radiology, MRI, PET, ultrasonography, nuclear medicine, theranostics, and other technologies) as well as novel applications of imaging for screening, diagnosis, prognosis, and treatment of disease across all medical specialties.
lunes, 23 de febrero de 2026
MCT Oil Benefits for Weight Loss, Metabolism, and Fat Burning
https://www.news-medical.net/health/MCT-Oil-Benefits-for-Weight-Loss-Metabolism-and-Fat-Burning.aspx
Medium-chain triglycerides are rapidly absorbed fats that increase postprandial energy expenditure, enhance fat oxidation, and stimulate ketogenesis, with modest but reproducible metabolic benefits in both lean and overweight individuals. Human evidence shows small reductions in subsequent energy intake, preserved metabolic effects in obesity, and largely neutral effects on major cholesterol markers when consumed in controlled doses.
Are you hardwired to have an affair? Justin Garcia | Guardian | February 23, 2026
https://geneticliteracyproject.org/2026/02/23/are-you-hardwired-to-have-an-affair/
As an evolutionary biologist who studies sex and relationships, I’m fascinated by these two truths. We humans make romantic commitments to each other – and some also break those commitments by cheating.
49ers injury conspiracy theory: Power-station radiation isn’t to blame, but anti-technology hysteria reigns PJ Seel | February 23, 2026
https://geneticliteracyproject.org/2026/02/23/49ers-injury-conspiracy-theory-power-station-radiation-isnt-to-blame-but-anti-technology-hysteria-reigns/
As a San Francisco 49ers fan since I was a child, it was painful to watch the Seattle Seahawks run roughshod over the Niners in the NFC divisional round of this year’s playoffs. Still, I was not disappointed to see the Seahawks go on to defeat the New England Patriots in the Super Bowl, held, sanguinely, at Levi’s Stadium in Santa Clara, California—the home of the 49ers.
A healthy breast microbiome may help prevent cancer Tamoxifen and a Mediterranean diet promoted bacterial communities that suppress breast tumor growth.
https://www.drugdiscoverynews.com/a-healthy-breast-microbiome-may-help-prevent-cancer-16278?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-948MB4VoaOX9MbzeHz8YVXjDE9QKN-nGWOXjT4Ptc047D-PfcnGbTDO1Z6nCVHhXqi4_kqSVsg06Nst8AYTWMhZX7jxg&_hsmi=405045738&utm_content=405045738&utm_source=hs_email
About ten years ago, scientists showed not only that there is a breast microbiome but also that there is a link between breast cancer and disturbances in this microbial community (1,2). Since then, Katherine Cook, a cancer biologist at Wake Forest School of Medicine, has explored strategies for altering the breast microbiome to make it more resistant to cancer. In 2018, her team showed that dietary choices restructure the gut and the breast microbiomes in distinct ways (3).
Microbes inside tumors reveal new drug targets and resistance mechanisms Researchers highlight how intra-tumoral microbiota shape tumor growth, drug resistance, and treatment response.
https://www.drugdiscoverynews.com/microbes-inside-tumors-reveal-new-drug-targets-and-resistance-mechanisms-16760?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8iFdNhKO73Mt-g3-Lfk64yYbw5PluVeXZ5CM1wSfMFl4i8UlEZBHCjUhfZoIX7W1p5yiIJ3XDI2G0u_xhDg30sxzQF5A&_hsmi=405045738&utm_content=405045738&utm_source=hs_email
Scientists are uncovering a hidden ecosystem inside cancer itself — the intra-tumoral microbiome.
Once dismissed as contamination, these microbes are now recognized as active participants in cancer biology, influencing tumor initiation, progression, and response to treatment. A new review published in Genes & Diseases outlines how these microbial communities could become valuable tools in precision oncology.
How fecal microbiota transplantation could transform cancer immunotherapy Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy.
https://www.drugdiscoverynews.com/how-fecal-microbiota-transplantation-could-transform-cancer-immunotherapy-17017?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--4kQ_C3KxJHBwe_rqWxQYVu8cqK5i8lORT7KPHNKa0aU1vwQQz1YFvl93OyUTJNW0xbUE10WDIkFXmVmluSfMRX6H4kw&_hsmi=405045738&utm_content=405045738&utm_source=hs_email
Over the past decade, scientists have learned that cancer is not driven by tumor cells alone. Disruptions in the gut microbiome have been linked to cancer development and progression through effects on genomic stability, immune evasion, and the tumor microenvironment.
Editorial Nonmetastatic nasopharyngeal carcinoma: in search of safer therapies The Lancet Regional Health – Americas +... +++
Editorial
Nonmetastatic nasopharyngeal carcinoma: in search of safer therapies
The Lancet Regional Health – Americas
https://www.thelancet.com/journals/lanam/issue/vol54nonull/PIIS2667-193X(25)X0013-2
E-cigarettes versus combination nicotine replacement therapy following a recent failed quit attempt: a pragmatic randomized trial through state tobacco quitlines
Theodore L. Wagenera katrina.vickerman@gmail.com ∙ Alice Hintona ∙ Theodore M. Braskya ∙ Yoo Jin Choa ∙ Laura A. Beebeb ∙ Michael S. Businelleb ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00362-X/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsenc=p2ANqtz-9Qu0ydj8CyT7n3d-QXbEF6ictiZQhQTGFPZbmirz4zxvfrquAAtu_1WgWEsH0s1gmsV3aSIIMdzPI7wYTUmlbJnBa4NA&_hsmi=404952625&utm_content=404691780&utm_source=hs_email
Intensity-modulated proton therapy vs intensity-modulated radiotherapy in nasopharyngeal carcinoma: a case–control study
Caineng Caoa,b,f ∙ Teeradon Treechairusameb,c,f ∙ Amir H. Safavib ∙ Yingzhi Wub ∙ Zhigang Zhangd ∙ Achraf Shamseddineb ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00363-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsenc=p2ANqtz-_MMevOAoYgeqVdNiFiGmL332dlvI6P__gCpatwqzHOR-izT7rxiILdL7E_lCZV0O2XGL4ZrG-x7MNO2is4bJOjqHlIOw&_hsmi=404952625&utm_content=404691780&utm_source=hs_email
Incidence rates of twelve chronic diseases/conditions in US adults: findings from a population-based study
Richard L. Nahina Nahinr@mail.nih.gov ∙ Termeh Feinbergb ∙ Hanna Grol-Prokopczykc ∙ Flavia P. Kaposd ∙ Kerri Murraye ∙ Remle Scottf ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00353-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsenc=p2ANqtz--5e2dtaT6_sVj4Un5RDbnsTh8jRFQh5cI6oD9G93m8RxpOWXIYzI2w0NC_w7QjjASdpIUWB35zxwBPw3oofeojofPBOQ&_hsmi=404952625&utm_content=404691780&utm_source=hs_email
Suscribirse a:
Comentarios (Atom)
.png)
.png)
